Developing Novel Dual Payload ADCs With Tailored Mechanistic Combinations to Address Diverse Clinical Challenges
- Introducing a pipeline of bispecific, dual payload ADCs combining multi-targeting and mechanistic innovations
- Contextualizing dual payload strategies combining Topo1 with an orthogonal or synergistic MoA to combat diverse resistance mechanisms
- Breaking down preclinical efficacy and safety data of dual payload programs and highlighting future clinical development plans